New malaria vaccine vivaxin enters first human tests

NCT ID NCT07172724

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Federal University of Minas Gerais Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new vaccine called Vivaxin, designed to protect against malaria caused by the Plasmodium vivax parasite. Researchers will give the vaccine to 48 healthy adults who have never had malaria, to check if it is safe and whether it triggers an immune response. The study is not yet recruiting and will compare the vaccine against a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vivaxin vaccine (a lyophilized antigen mixed with an adjuvant called CTVad)
What this could lead to: If successful, this could lead to a vaccine that prevents malaria caused by Plasmodium vivax, a major cause of illness worldwide.
What could go wrong: This is a very early Phase 1 trial with only 48 people, so it is primarily checking safety and immune response, not whether the vaccine actually prevents malaria. Many vaccines fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA VIVAX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria Plasmodium vivax malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA VIVAX

Contacts and locations

Locations

Centro de Pesquisas Clínicas (CPC) do Hospital das Clínicas (HC) da UFMG/ Filial Ebserh

Belo Horizonte, Minas Gerais, 30130-100, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.